Dr.NateNeph said:

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.

Saving this. It is the first explanation that did not require me to already understand it.

Clinical perspective, offered as context rather than as advice. The honest answer is that the effect is real, the magnitude is contested, and the individual variation is larger than either. Those three things can all be true at once, and most arguments here are two people holding different parts of that.

Dr.PainCLE said:

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The counter-case has not been addressed. Somebody upthread described the situation that does not fit, and the thread moved on rather than engaging with it, which is the failure mode this board is supposed to avoid.

Adding the numbers, since they settle part of this. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.